(Q45383263)

14 December 2017

Retrospective and prospective studies of hepatitis B virus reactivation in malignant lymphoma with occult HBV carrier (English)

1 reference

14 December 2017

1 reference

1 reference

N Fukushima

1

1 reference

14 December 2017

T Mizuta

2

1 reference

14 December 2017

M Tanaka

3

1 reference

14 December 2017

M Yokoo

4

1 reference

14 December 2017

M Ide

5

1 reference

14 December 2017

T Hisatomi

6

1 reference

14 December 2017

N Kuwahara

7

1 reference

14 December 2017

R Tomimasu

8

1 reference

14 December 2017

N Tsuneyoshi

9

1 reference

14 December 2017

N Funai

10

1 reference

14 December 2017

E Sueoka

11

1 reference

14 December 2017

26 June 2009

1 reference

14 December 2017

1 reference

14 December 2017

20

1 reference

14 December 2017

12

1 reference

14 December 2017

2013-2017

1 reference

Fulminant hepatitis B virus reactivation with concomitant listeriosis after fludarabine and rituximab therapy: case report

14 December 2017

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP230

Fatal hepatitis B virus reactivation by an escape mutant following rituximab therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP230

Delayed hepatitis B virus reactivation after cessation of preemptive lamivudine in lymphoma patients treated with rituximab plus CHOP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP230

A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP230

Preemptive use of interferon or lamivudine for hepatitis B reactivation in patients with aggressive lymphoma receiving chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP230

Reactivation of an occult hepatitis B virus escape mutant in an anti-HBs positive, anti-HBc negative lymphoma patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP230

Reactivation of resolved hepatitis B virus infection after allogeneic haematopoietic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP230

Hepatitis B virus reactivation in breast cancer patients receiving cytotoxic chemotherapy: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP230

Occult hepatitis B virus infection in hematopoietic stem cell donors in a hepatitis B virus endemic area.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP230

Progressive and sufficient decrease of hepatitis B core antibody can predict the disappearance of hepatitis B virus DNA in Japanese patients with hepatitis B surface antigen clearance

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP230

Reactivation of hepatitis B virus infection in an anti-HBc and anti-HBs positive patient after allogeneic bone marrow transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP230

Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP230

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDP230

1 reference

14 December 2017

1 reference